Dr. Hou on the Latest Updates With CAR T-Cell Therapy in DLBCL

Video

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

Jing-Zhou Hou, MD, PhD, co-chair of the Hematological Malignancies program, and medical oncologist, hematologist, and clinical instructor at University of Pittsburgh Medical Center Hillman Cancer Center, discusses the latest updates with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

At the 2019 ASCO Annual Meeting, updated data from the ZUMA trials with axicabtagene ciloleucel (axi-cel; Yescarta) were presented in the relapsed/refractory setting. At 24 months of follow-up, the complete response (CR) rate is 40% with an objective response rate of over 50%. The overall survival is also improved with this product. Axi-cel was initially approved by the FDA in October 2017 for use in patients with DLBCL. These data support further investigation into additional CAR T-cell products for transplant-ineligible patients, says Hou.

Data from the phase II JULIET trial which evaluated tisagenlecleucel (Kymriah)] were also published. Updated data showed an accordant response rate at 12-months of follow-up; specifically, the CR rate was 40% and the duration of response was relatively durable for those who had a CR.

The third trial, TRANSCEND-NHL-001 trial, is evaluating lisocabtagene maraleucel (JCAR017; liso-cel). The study has just completed accrual for a phase II trial.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.